Request A Call Back
Monuvir is a preparation of Molnupiravir. it is an antiviral drug that is orally active and is developed for the treatment of influenza. It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through the introduction of copying errors during viral RNA replication including SARS-CoV-2, the causative agent of COVID-19.
Molnupiravir is a shape-shifter, called a tautomer. It assumes two forms, one which closely resembles uracil and the other cytosine. Because it appears in these two different forms, once it is recorded, the replicating polymerase develops transition mutations, where a U nucleotide is converted to a C and a C to U. Copying RNA that contains Moinupiravir results in fatal flaws in the sequence, stopping replication, shortening infection, and limiting transmission. The difference between the structure of an authentic nucleotide and Molnupiravir is apparently too subtle to trigger removal by the exonuclease repair function of the viral polymerase, a function that has bedeviled these many other nucleoside inhibitors. INDICATIONS
Monuvir is an antiviral medicine used to treat mild to moderate COVID-19 (caused by SARS-CoV-2) in adults who are at risk for developing severe illness. Monuvir™ may help people with COVID-19 stay out of the hospital and feel better. Emergency use authorized ora therapeutic for the treatment of COVID-19 in Non-hospitalized patients with mild or moderate disease.
Asymptomatic or pre-symptomatic Infection: Individuals who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic(e.gpolymerase chain reaction) or antigen test but have no symptoms.
Mild illness: Individuals who have any of the various signs and symptoms of COVID-19(e.g. fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath dyspnoea, or abnormal chest imaging.
.Moderate iliness: Individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen(Sp02) 294% on room air at sea level. Severe illness: Individuals who have respiratory frequency >30 breaths per minute,Sp02<94% on room air at sea level,ratio of arterial partial pressure of oxygen to fraction of inspired oxygen(Pa02/Fi02)<300 mmHg,or lung infiltrates >50%.
Critical illness: Individuals who have respiratory failure,septic shock,and/or multiple organ dysfunction.
DOSAGE AND ADMINISTRATION
The recommended dose of Monuvir is four 200 mg capsules, every 12 hours for 5 days CONTRAINDICATIONS
Molnupiravir is contraindicated in patients with known hypersensitivity to Molnupiravin PRECAUTION AND WARNING
There are limited clinical data available for Molnupiravir. Serious and unexpected adverse events may occur that have not been previously reported with Molnupiravir use. USE IN PREGNANCY AND LACTATION
Animal studies with molnupiravir have shown harmful effects to the unborn animal. Monuvir is not recommended in pregnancy. Monuvir has not been studied in pregnancy and it is not known if Monuvir will harm your baby while you are pregnant.
If you are pregnant, think you may be pregnant,or are planning to have a baby, ask your doctor for advice.lf you can become pregnant, you should use effective birth control while you are taking Monuvir and for 4 days after the last dose of Monuvir
If you are breast-feeding or are planning to breastfeed,tell your doctor before taking this medicine.Breast-feeding is not recommended during treatment and for 4 days after the last dose of Monuvirm. This is because it is not known if Monuvir gets into breast milk and will be passed to the baby.
CHILDREN AND ADOLESCENTS
Do not give this medicine to children and adolescents aged less than 18 years. The use of Monuvir in persons aged less than 18 years have not yet been studied. PHARMACEUTICAL PRECAUTION
Store at or below 25C temperature. Keep away from light and wet places. Keep out of reach of children. PACKAGING
Monuvir 200 Capsule:
Box containing 1 strip of 10 capsules.Each capsule contains Molnupiravir 200 mg